Company intelligence / Profile preview

BryoLogyx Inc.

California, United Statesbryologyx.com ↗

Ownership: Private
Development stage: Phase 2

Overview

BryoLogyx is developing bryostatin-1 to enhance cancer immunotherapies by increasing tumor antigen expression. Clinical trials with the NCI were expected to begin in late 2020/early 2021, with initial focus on CD22+ B-cell acute lymphoblastic leukemia.

Therapeutic areas: Oncology
Modalities: Small molecule drugs
Industry: Biotech

Drug pipeline

1 asset

bryostatin-1

Pre-clinical

Indications: Cancer immunotherapy, B-cell acute lymphoblastic leukemia

Partnerships

National Cancer Institute (NCI)Stanford UniversityNeurotropetwo unnamed major biopharmaceutical companies

Beyond the preview

Go deeper on BryoLogyx Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BryoLogyx Inc..

Explore the full profile